Product Candidate
Discovery
Preclinical
PHASE 1
PHASE 2
PHASE 3
MARKET

Virology: Liver

HCV Protease Inhibitor
Glecaprevir-containing pan-genotypic 2-DAA combo
mavyret
HBV Core Inhibitor
EDP-514Viremic HBV patients
HBVCore Inhibitor
EDP-514NUC-suppressed HBV patients
HBVRNA Destabilizer
EDP-721

Virology: Respiratory

RSVN-Protein Inhibitor
EDP-938RSVP
RSVN-Protein Inhibitor
EDP-938RSVPEDs
RSVN-Protein Inhibitor
EDP-938RSVTx
RSVL-Protein Inhibitor
hMPV Non-Fusion Inhibitor
COVID-19 SARS-CoV-2 Inhibitor

Non-viral Liver Disease

NASH FXR Agonist
EDP-305ARGON-2
NASH FXR Agonist Follow-on
EDP-297

Discovery or Preclinical

RSV, HBV, NASH, Other

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed as MAVYRET (U.S.) and MAVIRET (ex-U.S.), it replaces VIEKIRA PAK (no longer sold in the U.S.) and VIEKIRAX (sold primarily in select jurisdictions where MAVIRET is not yet approved).